All In Biotech

NDA 020825 · Viatris

Geodon

Ziprasidone Hydrochloride · Oral · Atypical Antipsychotic

Novel

Last checked: Nov 20, 2026Latest source record: Jan 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2001

Feb 5, 2001

Approved uses

4

Original approval plus efficacy supplements

Registered trials

134

38 Phase 3, 2 recruiting

FAERS reports

17,662

12,204 serious, 1,238 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. GEODON is not approved for the treatment of patients with dementia-related psychosis [see Warnings and Precautions (5.1) ] . WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed warning. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. GEODON is not approved for the treatment of patients with dementia-related psychosis. ( 5.1 )

What it is approved for

From the label in effect Jan 15, 2025.

GEODON is indicated for the treatment of schizophrenia, as monotherapy for the acute treatment of bipolar manic or mixed episodes, and as an adjunct to lithium or valproate for the maintenance treatment of bipolar disorder. GEODON intramuscular is indicated for acute agitation in schizophrenic patients. When deciding among the alternative treatments available for the condition needing treatment, the prescriber should consider the finding of ziprasidone’s greater capacity to prolong the QT/QTc interval compared to several other antipsychotic drugs [see Warnings and Precautions (5.3) ] . Prolongation of the QTc interval is associated in some other drugs with the ability to cause torsade de pointes-type arrhythmia, a potentially fatal polymorphic ventricular tachycardia, and sudden death. In many cases this would lead to the conclusion that other drugs should be tried first. Whether ziprasidone will cause torsade de pointes or increase the rate of sudden death is not yet known [see Warnings and Precautions (5.3) ] . Schizophrenia • GEODON is indicated for the treatment of schizophrenia in adults [see Clinical Studies (14.1) ] . Bipolar I Disorder (Acute Mixed or Manic Episodes and Maintenance Treatment as an Adjunct to Lithium or Valproate) • GEODON is indicated as monotherapy for the acute treatment of adults with manic or mixed episodes associated with bipolar I disorder [see Clinical Studies (14.2) ] . • GEODON is indicated as an adjunct to lithium or valproate for the maintenance treatment of bipolar I disorder in adults [see Clinical Studies (14.2) ] . Acute Treatment of Agitation in Schizophrenia • GEODON intramuscular is indicated for the treatment of acute agitation in schizophrenic adult patients for whom treatment with ziprasidone is appropriate and who need...

Mechanism: The mechanism of action of ziprasidone in the treatment of the listed indications could be mediated through a combination of dopamine type 2 (D 2 ) and serotonin type 2 (5HT 2 ) antagonism.

Therapeutic areas: Psychiatry

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • GEODON · ZIPRASIDONE HYDROCHLORIDE EQ 20MG BASE · CAPSULE, ORAL · Prescription · TE AB
  • GEODON · ZIPRASIDONE HYDROCHLORIDE EQ 80MG BASE · CAPSULE, ORAL · Prescription · TE AB
  • GEODON · ZIPRASIDONE HYDROCHLORIDE EQ 40MG BASE · CAPSULE, ORAL · Prescription · TE AB
  • GEODON · ZIPRASIDONE HYDROCHLORIDE EQ 60MG BASE · CAPSULE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Ziprasidone" as an intervention, any sponsor and status, largest first.

All 134 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective1,438
  • weight increased1,185
  • diabetes mellitus1,004
  • anxiety883
  • type 2 diabetes mellitus859
  • insomnia806
  • depression792
  • somnolence750
  • fatigue727
  • tardive dyskinesia707
  • tremor699
  • nausea682

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004559
2005664
2006718
2007860
2008438
20091,102
20102,777
20111,613
20121,060
2013734
2014612
2015833
2016867
2017711
2018643
2019660
2020619
2021517
2022474
2023364
2024290
2025304
2026243

Recalls

1 FDA enforcement reports for this application.

  • Apr 13, 2022 · Class II · Terminated

    cGMP deviations: Temperature abuse

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Geodon (Ziprasidone HCl)

2024 spending

$5.4M

Beneficiaries

316

2,605 claims

Per beneficiary

$16,960

$27.89 per unit

View as table
YearSpending
2020$9,349,288
2021$7,824,572
2022$6,553,727
2023$6,284,899
2024$5,359,404

Part D: Geodon (Ziprasidone Mesylate)

2024 spending

$25K

Beneficiaries

44

129 claims

Per beneficiary

$558

$66.70 per unit

View as table
YearSpending
2020$507,913
2021$128,621
2022$53,079
2023$20,855
2024$24,547

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 511 on PubMed

Sponsor: Viatris

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.